clasping and wringing hands, shuffling feet, occasional restless walking, moderate night wakefulness. Affective~mild to moderate anxiousness, agitation, apprehension, irritability and secondary depression.
Subjective-anorexia, difficulty sleeping,. expressed feelings of stress or distress. GRADE II-Decompensated even under hospitalization.
Autonomic-signs as in Grade I.
Motor-motor restlessness -frequent or continual pacing, inability to stay with G.T. task, ward avocations, as reading, playing cards, knitting, by reason of restlessness and distractibility, frequent night restlessness.
Affective-irritability easily provoked, flashes of temper, moderately severe anxiousness, apprehension, agitation; importunity, mild but inappropriate elevation of mood, mild or moderate depression. GRADE III-Complete adjustive decompensation; loss of control; socially unassimilable.
Autonomic-signs as in Grades I and II. Motor-motor restlessness, greater than Grade II -useless continual interfering, aggressive or combative behaviour, inability to apply self to any occupation by reason of motor activity and distractibility; destructive; night wandering.
Affective-uncertain, hair-trigger irritability, rages, tantrums, extreme anxiousness or panic, elation or ecstasy.
Dosage and Administration of the Drug
In our study medication was started with parenteral and oral use of reserpine or identical placebo (the placebo tablet and ampules were identical in appearance to the active tablet), The ampules contained 2.5 mg. of preparation per c.c. and tablets 0.5 mg. Gradually we evolved the following general dosage plan which later was modified to meet individual requirements. (See Table V ). This dosage schedule was used in the early months of the study. Later dosage was increased sometimes to toxic levels then lowered to a maintenance dose. The daily dose ranged from 2 mg. P.O. and 5 mg. I.M., to 10 mg. P.O. and 30 mg. I.M. The maintenance dose was between 6 and 8 mg. orally.
The allocating of drug or placebo was done by the hospital pharmacist. The investigator was not aware which the patient was receiving. The investigator could change the preparation as he saw fit. From time to time the preparation was also changed by the pharmacist without the investigator's knowledge.
We revised our dosage as we went along. If patients did not show beneficial response the dosage was increased sometimes to toxic levels and complications treated accordingly. In case of improvement a maintenance dose was established with oral medication only. Some cases required decrease in dosage or use of methyl-phenidyl acetate (Ritalin) to combat depressive features.
W echose the combined parenteral-oral dosage schedule, firstly because it appears to be a more intensive therapy where results could be seen earlier, and secondly it was reported by Hollister (2) and his group that the frequency with which improvement occurred was greater in patients who received the combined therapy. The indication for therapy was always the same for both groups. From the original placebo group 27 patients were switched to reserpine and from the reserpine group 6 were switched to placebo, so that 60 patients received reserpine for a minimum time of 4 weeks. 33 patients were treated on placebo (on the same 4 week basis). All of the patients of this study received medication from 4 to 8 weeks with the exception of 7 patients who received medication for 1 week only. This latter group were discarded from evaluation because . of short term therapy (between 3 to 8 days), after which their discharge was arranged by the referring doctor. However, they were kept on an administrative basis and are included as far as symptoms and side effects are concerned. (See Table VI ). The majority of changes to the opposite medication were made between 3 and 5 weeks of medication.
The main symptoms in Distress -Grade I -were irritability in 50 patients, can not sit or relax in 54 patients, extreme feelings of stress in 50 patients, agitation in 34 patients, tremors in 40 patients, frequent shifting position in 29 patients, restless walking in 27 patients, trouble sleeping in 36 patients, depression in 16 patients, gastric distress in 22 patients, apprehension in 20 patients, anorexia in 12 patients. The main symptoms in Distress -Grade II -were agitation in 24 patients, pacing in 19 patients, distractibility and restlessness in 22 patients, "inappropriate mood" in 21 patients, severe anxiety in 15 patients, irritability easily provoked in 20 patients.
The main symptoms in Distress -Grade III -were uncertainty and irritability in 5 patients, aggressive behaviour in 4 patients, "continuous interfering" in 6 patients.
Clinical Evaluation of the Drug in 3 Grades of Distress
The results of sYfWltomatic improvement are shown on Tables IV, V and VI. There is a definitely higher percentage of improvement in the reserpine group, especially in Distress Grades I and II, whereas in Distress Grade III the results are approximately the same in both groups.
Psychological Tests
Those patients capable of being tested were examined by a psychologist. Intelligence Scores-49 patients co-operated in a complete Wechsler Bellevue Intelligence and Bender Gestalt scores". These patients were each tested twice prior to the project and once while off medication.
The Wechsler Bellevue scores were evaluated as follows:-A change of 5 or more weighted score points is considered a significant deviation. An arbitrary decision of 5 was made as this allows for a gain of one point in each of the subtest scores.
Group 1-21 patients (11 reserpine and 10 placebo) shows a significant improvement. Group 11-22 patients (15 reserpine and 7 placebo) shows no significant change. Group 111-3 patients (2 placebo and 1 reserpine) shows a significant loss in total score. In 3 patients it was not possible to get enough co-operation to obtain any Wechsler scores on either pre-or post-interview. (See Table VII ).
Results of Combined Tests in %
(See Table IX ).
·Wechsler Bellevue and Bender Gestalt scores were assigned as follows:
WECHSLER BELLEVUE SCORES o represents a change of less than 5 points for the patients in Group II only + represents a gain of 10 points or more. ++ represents a gain of 15 points or more. +++ represents a gain of 20 points or more.
represents a loss of 15 points or more. represents a change between 5 and 10 points for the worse.
BENDER GESTALT SCORES A meaningful change in score is defined as a change of at least 8 weighted score points. This is an arbitrary choice based on the' fact that the most marked deviations are assigned scores of 8 points.
(See Table VIII ).
From the last 19 patients 6 (5 reserpine and 1 placebo) were unable to produce the designs well enough on either testing to have a score calculated. Electroencephalography Two E.E.G.'s were obtained from 41 patients of this group. The first record was made prior to medication. The second was made within 24 to 48 hours after termination of the drug. There was no significant change in the number of normal and abnormal records on retesting either on placebo or reserpine. However, on reserpine there was some tendency towards improvement. One E.E.G. record had to be discarded as insufficient due to poor cooperation in the part of the patient.
A limited group of patients also had capillary (nailbeds) microscopic observations done by the Department of Neurological Research at the University of British Columbia to see the correlation with the clinical findings.
Capillaroscopy has been used in establishing a normal morphological pattern of the capillary structure as seen at the base of the fingernail. The present study was a co-ordinated longitudinal experiment on acute and chronic patients. A sample of 20 were placed on reserpine and photomicrographs were taken preand post-treatment. A sample of 4 were placed on placebo and also observed photomicrographically pre-and post-therapy. The grades of distress and clinical results following reserpine and placebo on patients who had the nailbed studies were correlated with the laboratory finding designated in a similar fashion. The computed correlation for the reserpine group of 0.342 was not significant at the 0.05 level. The placebo group was matched and the computed correlation of 0.855 was not significant at the 0.05 level. Therefore we must say that through capillaroscopy, over a short period of time, the morphological pattern did not alter with the clinical change. (See Table X -"The frequency distribution of totals within the basic patterns"). (Table XI shows the percentage distribution of the basic morphological patterns of the four groups; superimposed is the normal study of Gibson, Bosley and Griffiths). Table XII shows the number of patients who experienced various degrees of side effects. They appeared more slowly and were less annoying to the patient apparently than other tranquilizers. Some of the side reaction disappeared mainly during the first two weeks of therapy. Some required management especially in cases of depression where methyl-phenidyl acetate had to be used, and sometimes it was necessary to reduce the dosage. The symptoms which did not subside became objectively and subjectively less troublesome. Side effects like nasal stuffiness, increased appetite, flushing, paraesthesias, loose stools and cramps did not require special attention or decrease in dose. The other symptoms were handled on an individual basis to avoid discontinuation of the drug.
Side Effects
Parkinsonism was severe in only four cases but was reversible -and responded well to 3-phenyl-3 (~diethylaminoethyl)-2-6-dioxopiperidine hyydrochloride".
These patients did not object to their Parkinsonian symptoms. It may be of some psychophysiologic interest that only schizophrenics developed this sideeffect.
Six patients were switched from reserpine to placebo for the following reasons:-
The first patient developed severe tremor in the first week which became uncontrollable with methanesulfonate (cogentin). (Preparation 10,870, described in detail above, was not available at that time).
The second patient suffered -subjectively from numerous psychosomatic complaints prior to the project. These symptoms became more severe and in addition the patient showed passive unco-operativeness to the procedure with features of depression requiring KCT.
The third patient, a very tense individual who has seen many doctors for his alleged asthma and in particular "shortness of breath", was tried on chlorpromazine and meprobamate prior to hospitalization without response. He suddenly became very sensitive to reserpine, developed oedema of face and feet and became extremely unco-operative. After changing to placebo and supportive psychotherapy, symptoms subsided. "10,870 -Ciba was used for experimental purposes. 
Morphology
The fourth patient who showed relatively good response was changed to placebo to see whether he would maintain the same level of improvement, however no distinct change occurred.
The fifth patient developed first severe depression without response to methylphenidyl acetate and later Parkinsonism with excessive drooling and loss of associated movements. This picture did not change by reducing the dosage to minimum nor by counteracting it with cogentin.
The last patient experienced in the first week a marked drop in blood pressure -the systolic dropped to 45 mm. and the diastolic to between 5 and 15 mm. with a subsequent bradycardia of 50/m. Due to the fact that this pattern was a consistent reaction even at low dosage of oral medication, it was felt that a change of drug was indicated. Hypotensive effect became reversible immediately after the alternative drug was given without real syncope being seen.
Depression which was more intensive in the first week and gradually subsided was successfully treated with methyl-phenidyl acetate, the dose ranging between 30 and 60 mg. daily by mouth without greatly decreasing the dosage of reserpine. It is possibly an open question whether reserpine produces this effect directly or merely unveils an underlying condition which was already present and contraindicates the use of reserpine. Four placebo patients received methyl-phenidyl acetate and only one showed some response to it. Therefore, we may conclude that the combination of reserpine and methyl-phenidyl acetate has its place.
In one case 3 petit mal seizures occurred during the second week of reserpine on a daily dosage of 7 mg. The pre and post reserpine E.E.G. of this case was checked but showed no focal slow waves and was regarded within borderline normal limits. This patient had a history of "blackouts".
No deaths occurred in our group. In concluding we can say that the side effects can be cleared by reducing the dosage, with stimulants and with constant reassurance.
Discussion
The effect of reserpine and placebo was studied in 93 acute and chronic psychiatric patients to determine whether its use could be beneficial in three ... different grades of distress. We have tried to gather information on the following questions:-How effective is reserpine in 3 different degrees of distress?
In what grade of distress is reserpine most useful? Using the same therapeutic milieu was the placebo therapy of any value? Is reserpine effective on patients who resisted other psychiatric therapies? Is methyl-phenidyl acetate useful in combatting depression as a side effect of reserpine? Would a reserpine-methylphenidyl acetate combination he suitable for use in those cases? Is the effectiveness of 3-phenyl-3 (~diethyl-aminoethyl)-2-6-dioxopiperidine hydrochloride useful in attacking the Parkinson Syndrome caused by reserpine? Is the toxicity of reserpine reversible? It is well accepted today that a great part of treatment is always offered by ward activities and hospital milieu. Also of importance is the duration of the course and the dosage employed.
During our study it became evident that the success or failure depended to a great measure on the understanding, co-operation and enthusiasm of the medical and nursing staffs. Even the type of ward has some hearing on the action of reserpine. In the form of an anecdote one doctor said "when will you he finished with this reserpine patient -I want to start treatment?" Another example happened in the chronic setting of our hospital. Six patients with the same grade of distress were placed on the drug at the same time and on the same dosage but in two different wards. The attitude of the Charge Nurse and staff on the "C" ward was enthusiastic whereas the "A" ward staff had the attitude "these are hopeless cases and nothing will touch them".
Generally the "C" patients improved more quickly and maintained their remission much longer. It is true that we had a larger number of patients with post-medication relapse.
It must be stressed that the results given here are the immediate results. We have satisfied ourselves that the drug has a favorable influence on different grades of mental distress but longer periods of therapy, more vigorous dosage and observation will be necessary.
Frequent switches from placebo to reserpine were made for the following reasons:-In many instances placebo medication became so obvious, especially to the nursing staff, that a change was indicated. On the other hand the initial drowsiness was readily observable by the staff permitting distinction between reserpine and placebo. Other case were changed mainly because of poor response or showing very severe side effects and pressure from the staff "to do something" because of poor amenability to nursing procedures and destructiveness.
The results obtained in our study were not disappointing although they are not as spectacular as those reported by other investigators.
Analyzing the findings one could surmise that in Distress-Grades I and II the dosage was relatively sufficient, but it appears that a higher dose would be indicated in Grade III. It is true that the group in Distress Grade III was a small one on which to draw definite conclusions and further study with a larger group of this type of distress is indicated. Detailed results are listed in Tables  IV, V and VI. We have found a great percentage of symptomatic improvement also in the placebo group. Everybody realizes today that placebo is therapeutic in itself in some patients. In our study 3 long term paranoid schizophrenics responded so well to placebo that discharge was being considered. On the other hand we can say that reserpine is a useful drug. As a good example where improvement was obviously due to reserpine I will mention the case of an extremely agitated and disturbed female patient who did not respond to increased dosage of placebo but when switched to reserpine a tremendous change for the better was noticed. Here is an excerpt of a note written by the night nurse to the Charge Nurse -"Do you think you could get any kind of sedation order for Miss F. even though she is on the reserpine project. I have tried just about everything I can think of but nothing seems to work. Tonight she has most of the patients awake. Even when secluded she is banging on the door, shouting, etc. Sorry to be so complaining but I have just run out of ideas." The next day the patient was given 10 mg. I.M. reserpine, t.i.d. and her attitude and behaviour changed in less than 24 hours.
The preparation 10,870 was effective in counterbalancing the extrapyramidal syndrome.
We were not able to confirm the findings of Noce, Williams and Rapaport (3) that depressed patients on reserpine became alert and more sociable. This may be achieved by combining it with rnethyl-phenidyl acetate. Barsa and Kline (1) emphasized a turbulent phase. We have not been able to confirm this observation.
From the available evidence it is not unreasonable to suppose that placebo in a therapeutic milieu can be useful in the symptomatic relief of selected symptoms but neither medication is an effective substitute for intimate human contact.
Side effects, their importance and their management are reviewed. It is the author's experience that a large number of patients can receive proper dosages of reserpine provided the side effects are counterbalanced symptomatically, and this would be preferable to abandoning therapy or reducing the dosage below the beneficial levels. Summary 1. Reserpine seems to be effective in all three grades of distress with slightly better results in the 1st and 2nd grade, and there it will be most useful. Reserpine suppresses the affective component of the various psychopathological symptoms, thus often making it possible for the symptoms to take a favorable course.
2. Methyl-phenidyl acetate was useful in counterbalancing depressive factor induced in some patients by reserpine.
3. 3-phenyl-3 (~diethylaminoethyl)-2-6-dioxopiperidine hydrochloride is very useful in combatting the complication of the extrapyramidal syndrome induced by high dosage of reserpine. 4. It is the author's experience that a large number of patients can receive proper dosages of reserpine, provided the side effects are counterbalanced symptomatically, and this would be preferable to abandoning therapy or reducing the dosage below the beneficial levels. The toxicity of reserpine is reversible.
5. The percentage of patients who showed a meaningful improvement in psychological testing (Wechsler Bellevue and Bender Gestalt) are interesting. 22% of those on reserpine showed consistent meaningful improvement in combined scores and 22% of those on placebo showed meaningful improvement in combined scores. Among individuals, however there was generally a greater degree of improvement in the reserpine patients than in the placebo patients.
6. The post E.E.G. records do not show significant improvement except in a few records on the reserpine group.
7. Our study also confirms the findings in other papers that in some patients the good results last only as long as the drug is administered. The period of observation covered by this report is a brief one. Therefore there are still a number of questions incompletely answered.
2. Hollister, L. E., Kriegar, G., Kringel, A., Silver, M. I., Vol. 158: 11-15, May 7, 1955. Resume L'effet de la reserpine, amsi qu'un groupe-temoin recevant des placebos, furent observes dans un hopital, Cette etude avait pour but de constater si la reserpine etait efficace a trois degres de gravite differents. Chez un pourcentage eleve des malades, aucun traitement n'avait jusque la reussi, tan dis que vingt seulement etaient hospitalises pour la premiere fois. On commenca par administrer la reserpinevou un placebo identique, par les voies parenterale et orale. La dose quotidienne s'echelonnait entre, d'une part 2mg. par la voie orale et 5 mg. par la voie intramusculaire et d'autres part 10 mg. par la voie orale et 30 mg. par la voie intramusculaire. Plus tard, les doses furent adaptees aux besoins individuels. Par suite d'effets secondaires, deux autres medicaments furent egalement etudies: l'acetate de rnethyl-phenidyl (Ritaline) et le chlorhydrate de 3-phenyl-3 (~diethylaminoethyl)-2-6-dioxopiperidine (10,870). Avant le traitement nous fimes les tests suivants L Wechsler Bellevue et Bender Gestalt chez 49 patients, electro-encephalographie chez 41 et capillaroscopie chez 24. Nous avions des entrevues hebdomadaires avec les patients et prenions note de toute modification symptomatique perceptible. Sans mentionner tous les effets secondaires connus, nous en avons cependant releve les plus importants et en avons indique Ie traitement.
Les resultats montrent qu'aux degres de gravite I et II l'effet de la reserpine etait meilleur que ce!ui des placebos et qu'au degre III les resultats etaient egaux. Dans Ie cas des placebos, l'effet bienfaisant est peut-etre attribuable a l'enthousiasme pour Ie nouveau medicament et particulierement au fait que des mesures concretes furent prises pour soulager un groupe de patients selectionnes, Dans cette etude ni Ie patient ni Ie personnel soignant ne savaient que! medicament le patient recevait. Les effets secondaires furent neutralises par la Ritaline et Ie medicament connu SOllS Ie chiffre 10,870. Aucun changement frappant dans le degre de soulagement ne fut revele par les tests psychologiques, les electro-encephalogramrnes et l'etude des capillaires de la matrice ungeale.
Notre etude confirme la constatation d'autres auteurs que chez certains patients les effets bienfaisants durent seulement tant que Ie medicament est administre. Pour produire une amelioration sensible, le medicament doit etre donne pendant nne periode prolongee,
